Cell Communication Lab, Department of Oncology, University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK.
Trends Cancer. 2024 Mar;10(3):185-195. doi: 10.1016/j.trecan.2023.11.003. Epub 2023 Dec 8.
Colorectal cancer (CRC) is traditionally considered to be a genetically driven disease. However, nongenetic plasticity has recently emerged as a major driver of tumour initiation, metastasis, and therapy response in CRC. Central to these processes is a recently discovered cell type, the revival colonic stem cell (revCSC). In contrast to traditional proliferative CSCs (proCSCs), revCSCs prioritise survival over propagation. revCSCs play an essential role in primary tumour formation, metastatic dissemination, and nongenetic chemoresistance. Current evidence suggests that CRC tumours leverage intestinal stem cell plasticity to both proliferate (via proCSCs) when unchallenged and survive (via revCSCs) in response to cell-extrinsic pressures. Although revCSCs likely represent a major source of therapeutic failure in CRC, our increasing knowledge of this important stem cell fate provides novel opportunities for therapeutic intervention.
结直肠癌(CRC)传统上被认为是一种由遗传驱动的疾病。然而,非遗传可塑性最近已成为 CRC 中肿瘤起始、转移和治疗反应的主要驱动因素。这些过程的核心是最近发现的一种细胞类型,即再激活结肠干细胞(revCSC)。与传统的增殖性 CSC(proCSC)相比,revCSC 优先考虑生存而非增殖。revCSC 在原发性肿瘤形成、转移扩散和非遗传化疗耐药性中发挥着重要作用。目前的证据表明,CRC 肿瘤利用肠干细胞可塑性,在不受挑战时通过 proCSC 增殖,在应对细胞外压力时通过 revCSC 存活。虽然 revCSC 可能是 CRC 治疗失败的主要原因,但我们对这种重要干细胞命运的了解不断增加,为治疗干预提供了新的机会。